Boehringer Ingelheim And 3T Biosciences Enter Into A Second Partnership To Develop Next-Generation Cancer Immunotherapies January 10, 2024
Orion and MSD Announce Initiation of Two Ph 3 Trials of ODM-208/MK5684 in Certain Patients with Metastatic CRPC January 10, 2024
Nuvectis Pharma, Inc. Announces a Collaboration with Mayo Clinic to Evaluate NXP800 in an Investigator-Sponsored Clinical Trial in Cholangiocarcinoma January 10, 2024
Innate Pharma Announces Licensing Of A Fourth Natural Killer Cell Engager In Oncology To Sanofi January 10, 2024
Verastem Oncology Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet Therapeutics January 10, 2024
Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio January 10, 2024
AstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseases January 10, 2024
Merck to Acquire Harpoon Therapeutics, including HPN328 in certain patients with small cell lung cancer and neuroendocrine tumors January 10, 2024
Avenzo Therapeutics Announces Global License Of AVZO-021 (ARTS-021), A Clinical Stage CDK2 Inhibitor From Allorion Therapeutics January 10, 2024
ImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 Million January 10, 2024
Nona Biosciences Enters into a Global License Agreement with Pfizer for HBM9033, an MSLN-Targeted ADC January 10, 2024
Orion and Glykos announce research collaboration and licensing agreement to develop next-generation ADCs January 10, 2024
Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications January 10, 2024
Patients enrolled into the 3rd Dosing Cohort of Ph 1/2 Study of ONCT-534 in R/R Metastatic CRPC January 10, 2024
23ME-00610 Ph 1/2a trial in advanced neuroendocrine and ovarian cancer patient cohorts expanded January 10, 2024
Status of Ph 1/2 Study of ONCT-808 in Patients with R/R Aggressive B-cell Lymphoma announced January 10, 2024
Two Ph 3 Trials of Datopotamab Deruxtecan + Imfinzi Initiated in Patients Across Two Breast Cancer Subtypes January 10, 2024
Investigator-initiated Ph 1/2 Trial of Seclidemstat + Azacitidine to Treat Heme Cancers Resumes Patient Enrollment January 10, 2024
Enrollment Completed in Ph 3 Bridging Study of Uproleselan in Chinese Patients with R/R AML January 10, 2024
